Core Viewpoint - The Hang Seng Index has announced updates to the calculation method of the Hang Seng Hong Kong Stock Connect Innovative Drug Selection Index, which will take effect during the index review ending June 30, 2025, with changes to be implemented on September 8, 2025 [1] Group 1: Changes in Calculation Method - The selection criteria for stocks will be modified, including liquidity and industry requirements [1] - The thematic and fundamental factor requirements will be removed [1] - The method for selecting constituent stocks will be revised, along with adjustments to the weight limits [1]

Group 1 - The calculation method for the Hang Seng Hong Kong Stock Connect Innovative Drug Index will be updated [1] - New liquidity requirements will be added to the index calculation method [1] - Industry requirements will be modified, and thematic requirements will be removed [1] - The method for selecting constituent stocks will be revised [1] - These changes will take effect during the index review as of June 30, 2025, with constituent stock changes implemented on September 8, 2025 [1]

Group 1 - The Hang Seng Biotechnology Index will undergo updates in its calculation methodology, including new requirements for the Stock Connect trading eligibility and modifications to the selection criteria [1] - The number of constituent stocks in the Hang Seng Biotechnology Index will be fixed at 30 [1] - The listing history requirement will be removed, and a rapid inclusion mechanism will be introduced [1] Group 2 - The Hang Seng Hong Kong-US Biotechnology Index will also see updates, with the number of constituent stocks fixed at 40 [1]